| Year |
Citation |
Score |
| 2021 |
Jang SC, Economides KD, Moniz RJ, Sia CL, Lewis N, McCoy C, Zi T, Zhang K, Harrison RA, Lim J, Dey J, Grenley M, Kirwin K, Ross NL, Bourdeau R, et al. ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance. Communications Biology. 4: 497. PMID 33888863 DOI: 10.1038/s42003-021-02004-5 |
0.364 |
|
| 2020 |
Gundle KR, Deutsch GB, Goodman HJ, Pollack SM, Thompson MJ, Davis JL, Lee MY, Ramirez DC, Kerwin W, Bertout JA, Grenley MO, Sottero KHW, Beirne E, Frazier J, Dey J, et al. Multiplexed evaluation of microdosed antineoplastic agents in situ in the tumor microenvironment of patients with soft tissue sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32299817 DOI: 10.1158/1078-0432.Ccr-20-0614 |
0.602 |
|
| 2019 |
Hatton BA, Grenley M, Garnsey J, Shinde V, Huszar D, Burns C, Ditzler S, Merrell A, Dey J, Beirne E, Klinghoffer RA. Abstract 4136: Direct intratumoral microdosing via the CIVO® platform reveals anti-tumor immune responses induced by the SUMO inhibitor TAK-981 Cancer Research. 79: 4136-4136. DOI: 10.1158/1538-7445.Am2019-4136 |
0.744 |
|
| 2018 |
Brabetz S, Leary SES, Gröbner SN, Nakamoto MW, Şeker-Cin H, Girard EJ, Cole B, Strand AD, Bloom KL, Hovestadt V, Mack NL, Pakiam F, Schwalm B, Korshunov A, Balasubramanian GP, ... ... Dey J, et al. A biobank of patient-derived pediatric brain tumor models. Nature Medicine. PMID 30349086 DOI: 10.1038/S41591-018-0207-3 |
0.641 |
|
| 2017 |
Dey J, Deckwerth TL, Kerwin WS, Casalini JR, Merrell AJ, Grenley MO, Burns C, Ditzler SH, Dixon CP, Beirne E, Gillespie KC, Kleinman EF, Klinghoffer RA. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Scientific Reports. 7: 18007. PMID 29269870 DOI: 10.1038/S41598-017-18368-W |
0.463 |
|
| 2016 |
Dey J, Kerwin WS, Grenley MO, Casalini JR, Tretyak I, Ditzler SH, Thirstrup DJ, Frazier JP, Pierce DW, Carleton M, Klinghoffer RA. A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. Plos One. 11: e0158617. PMID 27359113 DOI: 10.1371/Journal.Pone.0158617 |
0.622 |
|
| 2016 |
Dey J, Kerwin W, Casalini J, Merrell A, Grenley M, Ditzler S, Dixon C, Burns C, Danilov AV, Klinghoffer R. Voruciclib Sensitizes High Risk Diffuse Large B Cell Lymphoma to BCL2 Inhibition Mediated Cell Death and Tumor Regression Blood. 128: 4167-4167. DOI: 10.1182/Blood.V128.22.4167.4167 |
0.377 |
|
| 2016 |
Dey J, Casalini J, Ditzler S, Biery M, Merrell A, Thirstrup D, Grenley M, Klinghoffer R. Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition Cancer Research. 76: 2835-2835. DOI: 10.1158/1538-7445.Am2016-2835 |
0.488 |
|
| 2015 |
Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, Klinghoffer RA, Palmisano M, Chopra R. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemotherapy and Pharmacology. PMID 26231955 DOI: 10.1007/S00280-015-2833-5 |
0.48 |
|
| 2015 |
Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, ... Dey J, et al. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Science Translational Medicine. 7: 284ra58. PMID 25904742 DOI: 10.1126/Scitranslmed.Aaa7489 |
0.743 |
|
| 2015 |
Klinghoffer R, Moreno-Gonzalez A, Carleton M, Grenley M, Hatton B, Frazier J, Kerwin W, Tretyak I, Hedin N, Dey J, Casalini J, Ditzler S, Olson J, Caffo N. Abstract A39: A platform to assess multiple therapy options simultaneously in a patient's own tumor Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-A39 |
0.756 |
|
| 2014 |
Klinghoffer R, Moreno-Gonzalez A, Carleton M, Frazier J, Grenley M, Tretyak I, Hedin N, Dey J, Casalini J, Hatton B, Ditzler S, Olson J, Pierce D, Filvaroff E, Caffo N. Abstract 3129: A platform to assess multiple therapy options simultaneously in a patient's own tumor Cancer Research. 74: 3129-3129. DOI: 10.1158/1538-7445.Am2014-3129 |
0.758 |
|
| 2013 |
Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, Elsaesser K, Kemp CJ, Neiman PE, Weiss WA, Olson JM, Tapscott SJ. Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics : Official Journal of the Dna Methylation Society. 8: 1254-60. PMID 24107773 DOI: 10.4161/Epi.26486 |
0.515 |
|
| 2013 |
Dey J, Dubuc AM, Pedro KD, Thirstrup D, Mecham B, Northcott PA, Wu X, Shih D, Tapscott SJ, LeBlanc M, Taylor MD, Olson JM. MyoD is a tumor suppressor gene in medulloblastoma. Cancer Research. 73: 6828-37. PMID 24092238 DOI: 10.1158/0008-5472.Can-13-0730-T |
0.617 |
|
| 2012 |
Dey J, Ditzler S, Knoblaugh SE, Hatton BA, Schelter JM, Cleary MA, Mecham B, Rorke-Adams LB, Olson JM. A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Molecular and Cellular Biology. 32: 4104-15. PMID 22869526 DOI: 10.1128/Mcb.00862-12 |
0.655 |
|
| 2012 |
Vij AG, Kishore K, Dey J. Effect of intermittent hypobaric hypoxia on efficacy & clearance of drugs. The Indian Journal of Medical Research. 135: 211-6. PMID 22446863 |
0.311 |
|
| 2012 |
Dey J, Tapscott SJ, Olson JM. Abstract 1431: A novel tumor-suppressor role of MyoD, a muscle differentiation factor, in mouse models of medulloblastoma Cancer Research. 72: 1431-1431. DOI: 10.1158/1538-7445.Am2012-1431 |
0.632 |
|
| 2009 |
Fayard B, Bianchi F, Dey J, Moreno E, Djaffer S, Hynes NE, Monard D. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Research. 69: 5690-8. PMID 19584287 DOI: 10.1158/0008-5472.CAN-08-4573 |
0.31 |
|
| Show low-probability matches. |